Utama › Kanser Payudara Triple-Negatif › Maryland › Baltimore
Kajian klinikal Kanser Payudara Triple-Negatif di Baltimore, MD
12 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar Baltimore (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Mengambil pesertaFasa 3
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Mengambil pesertaFasa 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Mengambil pesertaFasa 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Mengambil pesertaFasa 1
- United Theranostics, Glen Burnie · 9 mi jauh
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Mengambil pesertaFasa 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Mengambil pesertaFasa 3
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- dan 1 lagi
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Mengambil pesertaFasa 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Mengambil pesertaFasa 2/3
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Mengambil pesertaFasa 1
- United Theranostics, Glen Burnie · 9 mi jauh
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Mengambil pesertaFasa 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Mengambil pesertaFasa 2
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Mengambil pesertaFasa 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Kajian Kanser Payudara Triple-Negatif di bandar lain
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Arlington, VA20 kajian
- Atlanta, GA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
Kajian lain di Baltimore
- Kanser Paru-paru Bukan Sel Kecil60 kajian
- Kanser Payudara47 kajian
- Kanser Prostat43 kajian
- Kanser Paru-paru40 kajian
- Kanser (semua jenis)37 kajian
- Kanser Pankreas31 kajian
- Kanser Kolorektal31 kajian
- Kanser Metastatik28 kajian
- Obesiti26 kajian
- Kanser Pundi Kencing24 kajian
- Kegagalan Jantung24 kajian
- Kanser Ovari22 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.